Literature DB >> 17102982

Effects of metabotropic glutamate 2/3 receptor antagonists in the stress-induced hyperthermia test in singly housed mice.

Michihiko Iijima1, Toshiharu Shimazaki, Akie Ito, Shigeyuki Chaki.   

Abstract

RATIONALE: The stress-induced hyperthermia (SIH) test in mice has been widely used as models including some physiological aspects of psychiatric disorders. Mediated by the autonomic nervous system, SIH is commonly known to occur both before and during exposure to stress-inducing or anxiogenic situations. Recently, modulation of the group II metabotropic glutamate (mGlu) 2/3 receptor has been proposed as a novel therapeutic approach for psychiatric disorders.
OBJECTIVES: In the present study, we evaluated the efficacy of selective mGlu2/3 receptor antagonists and an mGlu2/3 receptor agonist in the SIH test.
RESULTS: mGlu2/3 receptor antagonists such as MGS0039 and LY341495 significantly and dose-dependently reduced SIH without affecting basal rectal temperatures. In contrast, mGlu2/3 receptor agonists such as MGS0008 were ineffective in the SIH test. The attenuation of SIH by MGS0039 was significantly blocked by pretreatment with WAY100635, a serotonin 1A receptor antagonist. In contrast, an AMPA receptor potentiator, CX546 failed to reduce the SIH.
CONCLUSIONS: Taken together, these results suggest that the blockade of mGlu2/3 receptor may prevent stress-induced autonomic hyperactivity, and that stimulation of the postsynaptic serotonin 1A receptor, but not AMPA receptor, may be involved in this action.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17102982     DOI: 10.1007/s00213-006-0618-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  31 in total

1.  Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models.

Authors:  A Kłodzińska; E Chojnacka-Wójcik; A Pałucha; P Brański; P Popik; A Pilc
Journal:  Neuropharmacology       Date:  1999-12       Impact factor: 5.250

2.  Metabotropic glutamate receptor regulation of extracellular glutamate levels in the prefrontal cortex.

Authors:  Roberto I Melendez; Peter W Kalivas
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

3.  Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7.

Authors:  John F Cryan; Peter H Kelly; Hans C Neijt; Gilles Sansig; Peter J Flor; Herman van Der Putten
Journal:  Eur J Neurosci       Date:  2003-06       Impact factor: 3.386

4.  MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.

Authors:  Shigeyuki Chaki; Ryoko Yoshikawa; Shiho Hirota; Toshiharu Shimazaki; Maoko Maeda; Naoya Kawashima; Takao Yoshimizu; Akito Yasuhara; Kazunari Sakagami; Shigeru Okuyama; Shigetada Nakanishi; Atsuro Nakazato
Journal:  Neuropharmacology       Date:  2004-03       Impact factor: 5.250

5.  Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors.

Authors:  Naoya Kawashima; Jun-ichi Karasawa; Toshiharu Shimazaki; Shigeyuki Chaki; Shigeru Okuyama; Akito Yasuhara; Atsuro Nakazato
Journal:  Neurosci Lett       Date:  2005-01-05       Impact factor: 3.046

6.  Stress-induced hyperthermia in singly housed mice.

Authors:  J A Van der Heyden; T J Zethof; B Olivier
Journal:  Physiol Behav       Date:  1997-09

7.  Behavioral and physiological mouse assays for anxiety: a survey in nine mouse strains.

Authors:  J Adriaan Bouwknecht; Richard Paylor
Journal:  Behav Brain Res       Date:  2002-11-15       Impact factor: 3.332

8.  Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740.

Authors:  Veerle Bergink; Herman G M Westenberg
Journal:  Int Clin Psychopharmacol       Date:  2005-11       Impact factor: 1.659

9.  Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex.

Authors:  M Sakaue; P Somboonthum; B Nishihara; Y Koyama; H Hashimoto; A Baba; T Matsuda
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

10.  Regulation by 5-HT1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex.

Authors:  Yukio Ago; Yutaka Koyama; Akemichi Baba; Toshio Matsuda
Journal:  Neuropharmacology       Date:  2003-12       Impact factor: 5.250

View more
  11 in total

1.  Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test.

Authors:  Kenichi Fukumoto; Michihiko Iijima; Shigeyuki Chaki
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

Review 2.  Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.

Authors:  John H Krystal; Sanjay J Mathew; D Cyril D'Souza; Amir Garakani; Handan Gunduz-Bruce; Dennis S Charney
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

3.  5-HT1A receptor blockade reverses GABA(A) receptor alpha3 subunit-mediated anxiolytic effects on stress-induced hyperthermia.

Authors:  Christiaan H Vinkers; Ruud van Oorschot; S Mechiel Korte; Berend Olivier; Lucianne Groenink
Journal:  Psychopharmacology (Berl)       Date:  2010-06-10       Impact factor: 4.530

4.  Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia.

Authors:  Joanna M Wierońska; Katarzyna Stachowicz; Francine Acher; Tomasz Lech; Andrzej Pilc
Journal:  Psychopharmacology (Berl)       Date:  2011-09-28       Impact factor: 4.530

5.  In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.

Authors:  Linda M Rorick-Kehn; Bryan G Johnson; Karen M Knitowski; Craig R Salhoff; Jeffrey M Witkin; Kenneth W Perry; Kelly I Griffey; Joseph P Tizzano; James A Monn; David L McKinzie; Darryle D Schoepp
Journal:  Psychopharmacology (Berl)       Date:  2007-03-24       Impact factor: 4.415

6.  The role of group II metabotropic glutamate receptors in cognition and anxiety: comparative studies in GRM2(-/-), GRM3(-/-) and GRM2/3(-/-) knockout mice.

Authors:  Bianca De Filippis; Louisa Lyon; Amy Taylor; Tracy Lane; Philip W J Burnet; Paul J Harrison; David M Bannerman
Journal:  Neuropharmacology       Date:  2014-08-23       Impact factor: 5.250

7.  Long-term occupational stress is associated with regional reductions in brain tissue volumes.

Authors:  Eva Blix; Aleksander Perski; Hans Berglund; Ivanka Savic
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

8.  The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT₁A signalling.

Authors:  Joanna M Wierońska; Francine C Acher; Anna Sławińska; Piotr Gruca; Magdalena Lasoń-Tyburkiewicz; Mariusz Papp; Andrzej Pilc
Journal:  Psychopharmacology (Berl)       Date:  2013-03-10       Impact factor: 4.530

9.  Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage.

Authors:  Marta Motolese; Federica Mastroiacovo; Milena Cannella; Domenico Bucci; Anderson Gaglione; Barbara Riozzi; Robert Lütjens; Sonia M Poli; Sylvain Celanire; Valeria Bruno; Giuseppe Battaglia; Ferdinando Nicoletti
Journal:  Mol Brain       Date:  2015-10-24       Impact factor: 4.041

Review 10.  Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.

Authors:  Shalini Dogra; P Jeffrey Conn
Journal:  Neuropharmacology       Date:  2021-06-25       Impact factor: 5.273

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.